Market Spotlight: Eating Disorders
|出版日期||內容資訊||英文 36 Pages
|焦點市場分析:飲食障礙 Market Spotlight: Eating Disorders|
|出版日期: 2020年07月21日||內容資訊: 英文 36 Pages||
This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Worldwide, Datamonitor Healthcare estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in females aged 10-19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.
In this demographic group, Datamonitor Healthcare forecasts the number of prevalent cases of eating disorders to increase to 38.1 million by 2026.
Edgemont's fluoxetine tablets, Eli Lilly's Prozac, and Takeda's Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.
The only industry-sponsored drug in active clinical development for eating disorders is in Phase II. Relamorelin, which targets ghrelin receptor, is the only therapy in active clinical development for eating disorders. It is being tested as a subcutaneous formulation.
The overall likelihood of approval of a Phase I eating disorders asset is 8.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 5.8 years from Phase I to approval, compared to 8.9 years in the overall psychiatry space.
All of the clinical trials for eating disorders have been in Phase III. The US leads in terms of the number of eating disorders clinical trials globally, while Germany leads the major European markets.
Clinical trial activity in the eating disorders space consists entirely of completed trials. Takeda has the highest number of completed clinical trials for eating disorders, with three trials.
Takeda leads industry sponsors with the highest number of Phase III clinical trials for eating disorders, followed by Johnson & Johnson.
LIST OF TABLES|